kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
Company profile
Ticker
KRON
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
KRON stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
21 Mar 24
8-K
Cost Associated with Exit or Disposal Activities
7 Mar 24
8-K
Other Events
5 Mar 24
8-K
Departure of Directors or Certain Officers
25 Jan 24
8-K
Other Events
18 Dec 23
8-K
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Cost Associated with Exit or Disposal Activities
2 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 59.63 mm | 59.63 mm | 59.63 mm | 59.63 mm | 59.63 mm | 59.63 mm |
Cash burn (monthly) | (no burn) | 823.50 k | 11.28 mm | 10.68 mm | 7.53 mm | 6.34 mm |
Cash used (since last report) | n/a | 4.93 mm | 67.45 mm | 63.89 mm | 45.04 mm | 37.93 mm |
Cash remaining | n/a | 54.70 mm | -7.82 mm | -4.27 mm | 14.59 mm | 21.70 mm |
Runway (months of cash) | n/a | 66.4 | -0.7 | -0.4 | 1.9 | 3.4 |
Institutional ownership, Q3 2023
68.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 3 |
Closed positions | 20 |
Increased positions | 13 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 36.60 bn |
Total shares | 41.22 mm |
Total puts | 0.00 |
Total calls | 20.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bischofberger Norbert W | 4.37 mm | $59.40 mm |
Omega Fund Management | 3.82 mm | $4.96 bn |
Omega Fund V | 3.82 mm | $0.00 |
BVF | 2.91 mm | $3.78 bn |
Belldegrun Arie | 2.77 mm | $37.58 mm |
Vida Ventures Advisors | 2.77 mm | $3.59 bn |
Perceptive Advisors | 1.75 mm | $2.28 bn |
Vanguard | 1.69 mm | $2.19 bn |
Partners Capital Investment | 1.67 mm | $2.17 bn |
Artal | 1.54 mm | $2.01 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Feb 24 | Elizabeth A Olek | Common Stock | Sell | Dispose S | No | No | 1.0539 | 7,368 | 7.77 k | 193,275 |
21 Feb 24 | Charles Y Lin | Common Stock | Sell | Dispose S | No | No | 1.0539 | 12,036 | 12.68 k | 234,603 |
21 Feb 24 | Allison Frisbee | Common Stock | Sell | Dispose S | No | No | 1.0539 | 12,105 | 12.76 k | 204,510 |
News
Recap: Kronos Bio Q4 Earnings
21 Mar 24
Kronos Bio Q4 EPS $(0.43) Beats $(0.52) Estimate, Sales $2.29M Beat $1.52M Estimate, Cash Balance of $175.0M
21 Mar 24
Kronos Bio Announces 21% Reduction In Workforce, Restructuring To Focus Resources On Clinical Development With Extended Cash Runway Into The Second Half Of 2026
7 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Jan 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Jan 24